Top

Published in:

01-11-2010 | Brief Report

Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer

Authors: Dmitri Pchejetski, Joao Nunes, Lysann Sauer, Jasmin Sidhu, Anand Sharma, Hector C. Keun, Jonathan Waxman, Justin Stebbing

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Abstract

Weight gain in women receiving chemotherapy for breast cancer is associated with a higher risk of recurrence. Using metabonomic profiling, we recently reported that plasma lactate and alanine were prognostic for weight gain in individuals with breast cancer receiving chemotherapy. The role of lipid second messengers has not been studied. We assessed serum levels of sphingosine-1-phosphate (S1P), a known secreted lipid second messenger with a role in cell growth, in sequential samples from post-menopausal women receiving standard chemotherapy for early breast cancer and correlated these with body mass measurements and metabonomic profiling. While serum S1P levels prior to treatment did not correlate with body weight changes or circulating alanine and lactate, S1P levels measured during therapy were inversely correlated with weight gain (P = 0.04), but not weight loss (P = 0.74) or no change in weight (P = 0.5), suggesting a role of dynamic circulating S1P in adipocyte growth. These data provide evidence for an association between serum S1P and weight gain during chemotherapy cycles in women with breast cancer. Lipid second messengers have a role in chemotherapy-induced weight gain in breast cancer.

Available only for authorised users

Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN, Stefanick ML, Faerber S, Pierce JP (1999) Factors associated with weight gain in women after diagnosis of breast cancer. Women’s Healthy Eating and Living Study Group. J Am Diet Assoc 99(10):1212–1221PubMedCrossRef

Demark-Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, Blackwell K, Rimer BK (2001) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 19(9):2381–2389PubMedCrossRef

Dixon JK, Moritz DA, Baker FL (1978) Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum 5(3):5–7PubMed

Donegan WL, Hartz AJ, Rimm AA (1978) The association of body weight with recurrent cancer of the breast. Cancer 41(4):1590–1594PubMedCrossRef

Huntington MO (1985) Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast. Cancer 56(3):472–474PubMedCrossRef

Goodwin PJ (2001) Weight gain in early-stage breast cancer: where do we go from here? J Clin Oncol 19(9):2367–2369PubMedCrossRef

Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20(4):1128–1143PubMedCrossRef

Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378PubMedCrossRef

Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, Habel L, Jones L, Newman VA, Rock CL, Slattery ML et al (2006) Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 99(1):47–57PubMedCrossRef

10.

Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AM (2008) Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072–4077PubMedPubMedCentralCrossRef

11.

Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P et al (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776PubMedCrossRef

12.

Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, Al-Delaimy WK, Thomson CA, Kealey S, Hajek R et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol 25(17):2345–2351PubMedCrossRef

13.

Keun HC, Sidhu J, Pchejetski D, Lewis JS, Marconell H, Patterson M, Bloom SR, Amber V, Coombes RC, Stebbing J (2009) Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin Cancer Res 15(21):6716–6723PubMedCrossRef

14.

Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4(8):604–616PubMedCrossRef

15.

Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 103(44):16394–16399PubMedPubMedCentralCrossRef

16.

Hla T (2003) Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47(5):401–407PubMedCrossRef

17.

Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ (2001) Lysophospholipids–receptor revelations. Science 294(5548):1875–1878PubMedCrossRef

18.

Payne SG, Milstien S, Spiegel S (2002) Sphingosine-1-phosphate: dual messenger functions. FEBS Lett 531(1):54–57PubMedCrossRef

19.

Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ, Vadas MA (1998) Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 95(24):14196–14201PubMedPubMedCentralCrossRef

20.

Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA (2003) The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. Faseb J 17(11):1411–1421PubMedCrossRef

21.

Sato K, Ishikawa K, Ui M, Okajima F (1999) Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells. Brain Res 74(1–2):182–189

22.

Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF, Yun JK (2008) Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 49(5):948–954PubMedCrossRef

23.

French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63(18):5962–5969PubMed

24.

Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M (2008) Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1):41–52PubMedCrossRef

25.

Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW (2005) Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64(8):695–705PubMedCrossRef

26.

Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS, Li M (2008) Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 14(21):6996–7003PubMedCrossRef

27.

Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX et al (2009) Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 15(4):1393–1399PubMedCrossRef

28.

English D, Welch Z, Kovala AT, Harvey K, Volpert OV, Brindley DN, Garcia JG (2000) Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. Faseb J 14(14):2255–2265PubMedCrossRef

29.

Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S, Tigyi G, Igarashi Y et al (2000) Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96(10):3431–3438PubMedCrossRef

30.

Hanel P, Andreani P, Graler MH (2007) Erythrocytes store and release sphingosine 1-phosphate in blood. Faseb J 21(4):1202–1209PubMedCrossRef

31.

Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Osima N, Yokota H, Ikeda H, Yatomi Y (2008) Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem 45(Pt 4):356–363PubMedCrossRef

32.

Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N, Sabbadini RA (2003) Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 146(1):62–68PubMedCrossRef

33.

Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, Wargovich MJ, Reddy BS, Hannun YA, Obeid LM et al (2006) Sphingosine kinase 1 is up-regulated in colon carcinogenesis. Faseb J 20(2):386–388PubMedCrossRef

34.

Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K et al (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(7):1185–1191PubMedCrossRef

35.

Boneva-Asiova Z, Boyanov MA (2008) Body composition analysis by leg-to-leg bioelectrical impedance and dual-energy X-ray absorptiometry in non-obese and obese individuals. Diabetes Obes Metab 10(11):1012–1018PubMedCrossRef

36.

Edsall LC, Spiegel S (1999) Enzymatic measurement of sphingosine 1-phosphate. Anal Biochem 272(1):80–86PubMedCrossRef

37.

Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, Waxman J, Malavaud B, Cuvillier O (2008) Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 7(7):1836–1845PubMedCrossRef

38.

Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497–509PubMedCrossRef

39.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B et al (2005) Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 65(24):11667–11675PubMedCrossRef

40.

Pischon T, Nothlings U, Boeing H (2008) Obesity and cancer. Proc Nutrition Soc 67(2):128–145CrossRef

41.

Vona-Davis L, Rose DP (2009) Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 20(3):193–201PubMedCrossRef

42.

Takabe K, Paugh SW, Milstien S, Spiegel S (2008) “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60(2):181–195PubMedCrossRef

43.

Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, Cuvillier O (2006) Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20(1):95–102PubMedCrossRef

44.

Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D (2009) Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer 125(11):2728–2736PubMedCrossRef

45.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C (2009) Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8(4):809–820PubMedCrossRef

46.

Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S, Spiegel S (2008) Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. Faseb J 22(8):2629–2638PubMedPubMedCentralCrossRef

47.

Jun DJ, Lee JH, Choi BH, Koh TK, Ha DC, Jeong MW, Kim KT (2006) Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology 147(12):5835–5844PubMedCrossRef

48.

Jobgen W, Fu WJ, Gao H, Li P, Meininger CJ, Smith SB, Spencer TE, Wu G (2009) High fat feeding and dietary l-arginine supplementation differentially regulate gene expression in rat white adipose tissue. Amino Acids 37(1):187–198PubMedCrossRef

49.

Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS et al (2006) Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3):225–238PubMedCrossRef

50.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Eng J Med 362(5):402–415CrossRef

51.

Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Eng J Med 362(5):387–401CrossRef

Title: Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer
Authors: Dmitri Pchejetski
Joao Nunes
Lysann Sauer
Jasmin Sidhu
Anand Sharma
Hector C. Keun
Jonathan Waxman
Justin Stebbing
Publication date: 01-11-2010
Publisher: Springer New York
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0968-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer

Quantitative assessment of the effect of FGFR2 gene polymorphism on the risk of breast cancer

Association of a TGF-β1 gene −509 C/T polymorphism with breast cancer risk: a meta-analysis

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors?

Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes

The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer